Compare Stocks → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison CVE:CYPTSE:ONC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYPCypress DevelopmentC$1.09+1.4%C$1.09C$0.84▼C$2.14C$159.72MN/A71,527 shs33,605 shsONCOncolytics BiotechC$1.49+1.4%C$1.44C$1.20▼C$4.49C$112.38M1.4977,267 shs62,335 shsThe 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYPCypress Development0.00%0.00%0.00%0.00%0.00%ONCOncolytics Biotech+2.80%+2.08%+5.00%-13.53%-5.16%Mysterious Gold Leverage Just Announced (Ad)World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYPCypress DevelopmentN/AN/AN/AN/AN/AN/AN/AN/AONCOncolytics Biotech0.6152 of 5 stars3.50.00.00.00.90.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYPCypress DevelopmentN/AN/AN/AN/AONCOncolytics Biotech3.00BuyC$6.00302.68% UpsideCurrent Analyst RatingsLatest CYP, IMU, and ONC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2024ONCOncolytics BiotechRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperformC$3.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYPCypress DevelopmentN/AN/AC$0.24 per share4.49C$0.39 per shareN/AONCOncolytics BiotechN/AN/AC$0.35 per share4.22C$0.37 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYPCypress DevelopmentN/A-C$0.03N/A∞N/AN/AN/AN/AN/AONCOncolytics Biotech-C$27.75M-C$0.41N/A∞N/AN/A-102.66%-55.47%5/3/2024 (Estimated)Latest CYP, IMU, and ONC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/7/2024Q4 2023ONCOncolytics Biotech-C$0.15-C$0.05+C$0.10-C$0.05N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYPCypress DevelopmentN/AN/AN/AN/AN/AONCOncolytics BiotechN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYPCypress Development1.5042.8342.15ONCOncolytics Biotech1.549.018.86OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYPCypress DevelopmentN/AONCOncolytics Biotech6.98%Insider OwnershipCompanyInsider OwnershipCYPCypress DevelopmentN/AONCOncolytics Biotech6.24%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCYPCypress DevelopmentN/A146.53 millionN/ANot OptionableONCOncolytics Biotech2975.42 millionN/ANot OptionableCYP, IMU, and ONC HeadlinesSourceHeadlineKrystal Biotech gets grant for pharmaceutical composition for cancer treatment using recombinant HSV-1 viruspharmaceutical-technology.com - April 23 at 9:08 AMOutrun Therapeutics announces launch with $10m seed fundingpharmaceutical-technology.com - April 18 at 7:38 AMBiotech expansion for Japanese firm in Holly Springs driven by talent pool, universitiescarolinapublicpress.org - April 17 at 10:38 AMStocks in play: Oncolytics Biotech® Inc.ca.finance.yahoo.com - April 11 at 3:56 PMOncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDAfinance.yahoo.com - April 11 at 8:38 AMTransgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024markets.businessinsider.com - April 10 at 6:01 PMOncolytics Biotech is undervalued, Raymond James sayscantechletter.com - April 5 at 3:37 PMOncolytics Biotech (TSE:ONC) Trading Up 10.7%marketbeat.com - April 4 at 10:46 AMClosing Bell: Oncolytics Bio down on Friday (ONC)theglobeandmail.com - March 16 at 10:14 AMFutures Retreat Sharplymsn.com - March 11 at 4:05 PMOncolytics Biotech Inc.: Oncolytics Biotech Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCANfinanznachrichten.de - March 6 at 4:39 PMEcon Corp Services DBA Investorideas.com: Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winningfinanznachrichten.de - March 6 at 4:39 PMA Preview Of Oncolytics Biotech's Earningsbenzinga.com - March 6 at 4:39 PMOncolytics Biotech Inc ONCmorningstar.com - March 2 at 6:22 PMReiterating Buy Rating: Expanding Potential of Pelareorep in Oncolytics Biotech’s Pipelinemarkets.businessinsider.com - February 15 at 9:24 AMCancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatmentsfinance.yahoo.com - February 15 at 9:24 AMAnal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapiestheglobeandmail.com - February 14 at 2:36 PMUSA News Group: Pancreatic Cancer Treatments Poised for Major Advances in 2024finanznachrichten.de - February 7 at 11:03 AMKaliVir Announces Opening of GMP Cleanroom Facility, Increasing Manufacturing Capacity for Oncolytic Virusesfinance.yahoo.com - January 31 at 8:47 PMOncolytics Biotech Stock (NASDAQ:ONCY), Analyst Ratings, Price Targets, Predictionsbenzinga.com - January 6 at 3:30 PMJonesTrading Keeps Their Hold Rating on TRACON Pharmaceuticals (TCON)markets.businessinsider.com - December 14 at 8:26 AMOncolytics Biotech Inc.: Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCSfinanznachrichten.de - December 7 at 8:30 AMOncolytics Provides Update on Pancreatic Cancer Program for Pelareorepfinance.yahoo.com - November 9 at 7:48 AMOncolytics Biotech's Earnings Outlookbenzinga.com - November 3 at 6:37 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCypress DevelopmentCVE:CYPCypress Development Corp. engages in the acquisition, exploration, evaluation, and development of mineral properties in the United States and Canada. It explores for lithium, zinc, and silver deposits. The company's flagship project is the Clayton Valley project that covers an area of approximately 5,430 acres located in southwest Nevada. Cypress Development Corp. was incorporated in 1991 and is headquartered in Vancouver, Canada.Oncolytics BiotechTSE:ONCOncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.